HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Short Interest Update

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 332,424 shares, a drop of 12.6% from the December 31st total of 380,391 shares. Based on an average daily trading volume, of 74,544 shares, the days-to-cover ratio is presently 4.5 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 74,544 shares, the days-to-cover ratio is presently 4.5 days.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HCM. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Jefferies Financial Group upgraded shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, HUTCHMED presently has an average rating of “Hold” and an average price target of $20.88.

Hedge Funds Weigh In On HUTCHMED

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HCM. M&G PLC increased its stake in shares of HUTCHMED by 0.4% in the 2nd quarter. M&G PLC now owns 259,617 shares of the company’s stock valued at $3,894,000 after acquiring an additional 924 shares during the last quarter. Amundi increased its stake in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares in the last quarter. Jane Street Group LLC increased its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares in the last quarter. UBS Group AG raised its holdings in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after purchasing an additional 72,614 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after purchasing an additional 7,342 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Performance

HCM stock opened at $14.39 on Wednesday. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $19.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51. The business’s fifty day moving average is $14.30 and its 200-day moving average is $15.34.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.